Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of JZP441 in Healthy Adult Participants: A Double-Blind, Randomized, Placebo-Controlled Phase 1 Study
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Pharmacokinetic Parameter Accumulation Ratio of JZP441
研究概览
简要总结
Treatments for narcolepsy and hypersomnolence disorders should have good oral bioavailability and brain penetration properties. JZP441 has demonstrated wake-promoting efficacy and anticataplectic activity in nonclinical studies and may represent a novel approach for these patients.
详细描述
This Phase 1, double-blind, randomized, placebo-controlled, parallel group study is designed to characterize the safety, tolerability, and PK of multiple ascending doses of JZP441 for up to 4 weeks in healthy adult participants.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Is 18 to 50 years of age inclusive, at the time of signing the informed consent
- •Are overtly healthy as determined by medical evaluation, including medical history, physical exam, laboratory tests, and cardiac/blood pressure monitoring.
排除标准
- •History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that, in the investigator opinion, may interfere with absorption, distribution, metabolism, or excretion of drugs
- •Presence of renal impairment or calculated eGFR < 80 mL/min/1.73 m^
- •Triplicate 12-lead ECG demonstrating a mean QTcF > 450 msec for males and > 470 msec for females or any other clinically significant ECG abnormality per investigator assessment prior to dose of study intervention
- •Presence or history of significant cardiovascular disease including (but not limited to): myocardial infarction, uncontrolled hypertension, systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg (at Screening or baseline consistent with protocol specifications), angina pectoris, clinically significant arrhythmias, clinically significant valvular heart disease, history of any revascularization procedures or second or third degree heart block with/without a pacemaker, heart failure, or family history of Torsades de Pointes
- •Current diagnosis of or receiving treatment for depression; past (within 5 years) clinically significant major depressive episode; history of suicide attempt, current suicidal risk as determined from history, or presence of active suicidal ideation as indicated by a positive response to item 4 or item 5 on the C-SSRS (within the past 6 months)
- •History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or clinically significant psychiatric disorders, including other psychotic disorders
- •History (within past 2 years at Screening) or presence of substance use disorder (including alcohol) or seeking treatment for alcohol or substance abuse related disorder
- •History of seizure disorder or a physical condition that would increase seizure risk
- •History of head trauma or concussions that are deemed clinically significant by the investigator
- •Have used tobacco products or products for smoking cessation within 90 days before screening, including nicotine-containing products, or history of significant use of tobacco (> 10 cigarettes or equivalent per day) within 1 year before Screening, or unwilling to refrain from nicotine-containing products for the duration of the study
- •Participants who are taking a concomitant medication or supplement that lowers seizure threshold (eg, kratom)
- •Participants who have recently (< 2 weeks) discontinued a drug or supplement for which discontinuation would lower seizure threshold (eg, benzodiazepine medication)
- •Participation in a previous JZP441 clinical study
- •Positive alcohol test or urine drug screen (including cannabinoids and cotinine) at Screening or at any point throughout the duration of the study
- •Presence at Screening of HIV antibody, Hepatitis B surface antigen, Hepatitis C antibody, or a clinical history of these infections
- •History of clinically significant acute or chronic insomnia within the last 5 years
研究组 & 干预措施
JZP441
Healthy participants who will be randomized to receive an oral dose of JZP441.
干预措施: JZP441 (Drug)
Placebo
Healthy participants who will be randomized to receive placebo.
干预措施: Placebo (Drug)
结局指标
主要结局
Pharmacokinetic Parameter Accumulation Ratio of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Accumulation ratio (Cmax) and accumulation ratio (AUC) will be assessed.
Pharmacokinetic Parameter Maximum Plasma Concentration (Cmax) Levels of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Pharmacokinetic Parameter Time to Maximum Plasma Concentration (Tmax) of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Time to maximum plasma concentration (Tmax), time of maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Tmax1), and time of maximum observed plasma concentration post second dose during the 24-hour dosing interval (Tmax2), and time of last quantifiable concentration (Tlast) will be assessed.
Pharmacokinetic Parameter Apparent Oral Clearance (CL/F) of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Pharmacokinetic Parameter Area Under the Concentration-Time Curve (AUC) of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Area under the concentration-time curve from time 0 to 24 hours (AUC0-24), area under the concentration-time curve from time zero to time of the last quantifiable concentration (AUC0-last), and area under the concentration-time curve from time zero extrapolated to infinity (AUC∞) will be assessed.
Dose Proportionality of JZP441 for Maximum Concentration (Cmax)
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Dose proportionality of maximum concentration (Cmax), maximum observed plasma concentration post first dose but before second dose during the 24-hour dosing interval (Cmax1), and maximum observed plasma concentration post second dose during the 24-hour dosing interval (Cmax2) will be assessed.
Number of Participants With Treatment-emergent Adverse Events
时间窗: Day 1 up until 38 days after last dose of study drug, up to approximately 2 months
Pharmacokinetic Parameter Terminal Elimination Half-life (T1/2) of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Pharmacokinetic Parameter Apparent Volume of Distribution (Vz/F) of JZP441
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Dose Proportionality of JZP441 for Area Under the Concentration-Time Curve (AUC)
时间窗: Pre-dose and multiple post-dose timepoints, up to Day 28
Dose proportionality of area under the concentration-time curve from 0 to 24 hours (AUC\[0-24\]) will be assessed.
次要结局
未报告次要终点